Vanda Pharmaceuticals Stock Price, News & Analysis (NASDAQ:VNDA) $4.04 +0.08 (+2.02%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$3.95▼$4.1150-Day Range$3.38▼$4.5852-Week Range$3.30▼$11.04Volume652,518 shsAverage Volume790,740 shsMarket Capitalization$232.43 millionP/E Ratio19.24Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Vanda Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy3.55% of Shares Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment0.88Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.01) to ($0.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector385th out of 957 stocksBiotechnology Industry22nd out of 67 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Vanda Pharmaceuticals. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.55% of the outstanding shares of Vanda Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently increased by 21.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVanda Pharmaceuticals has received a 61.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Tasimelteon", "Antipsychotics", and "Clinical research services for psychotic disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for Vanda Pharmaceuticals is -1.77. Previous Next 3.3 News and Social Media Coverage News SentimentVanda Pharmaceuticals has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Vanda Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for VNDA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.70% of the stock of Vanda Pharmaceuticals is held by insiders.Percentage Held by Institutions97.92% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Vanda Pharmaceuticals are expected to decrease in the coming year, from ($0.01) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is 19.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.28.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is 19.24, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.82.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vanda Pharmaceuticals Stock (NASDAQ:VNDA)Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.Read More VNDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VNDA Stock News HeadlinesDecember 5, 2023 | bizjournals.comD.C.'s Vanda Pharmaceuticals scores FDA review of key drug after multiyear battleDecember 5, 2023 | finance.yahoo.comVanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis DrugDecember 7, 2023 | Edge On The Street (Ad)Americans Now Favor Gold Over Stocks as an Investment VehicleAmericans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges. December 4, 2023 | finance.yahoo.comVanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of GastroparesisDecember 3, 2023 | americanbankingnews.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Up 21.4% in NovemberNovember 11, 2023 | finance.yahoo.comOne Analyst Thinks Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Revenues Are Under ThreatNovember 10, 2023 | finance.yahoo.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comVanda Pharmaceuticals Announces Participation at November 2023 Investor ConferencesDecember 7, 2023 | Edge On The Street (Ad)Americans Now Favor Gold Over Stocks as an Investment VehicleAmericans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges. November 9, 2023 | finance.yahoo.comQ3 2023 Vanda Pharmaceuticals Inc Earnings CallNovember 8, 2023 | msn.comVanda Pharmaceuticals (VNDA) Reports Break-Even Earnings for Q3November 8, 2023 | msn.comVanda Pharmaceuticals GAAP EPS of $0.00 beats by $0.04, revenue of $38.82M misses by $5.68MNovember 8, 2023 | finance.yahoo.comVanda Pharmaceuticals Reports Third Quarter 2023 Financial ResultsNovember 8, 2023 | finance.yahoo.comVanda Pharmaceuticals Inc (VNDA) Faces Revenue Decline Amid Generic Competition in Q3 2023November 8, 2023 | markets.businessinsider.comVanda Pharmaceuticals earnings preview: what Wall Street is expectingNovember 7, 2023 | msn.comVanda Pharmaceuticals Q3 Earnings PreviewNovember 1, 2023 | finance.yahoo.comVanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023October 20, 2023 | bizjournals.comD.C.'s Vanda Pharmaceuticals to ask Supreme Court to review patent infringement lawsuitOctober 20, 2023 | finance.yahoo.comVanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA LitigationOctober 16, 2023 | msn.comVanda Pharmaceuticals: Value In The Biotech SpaceOctober 5, 2023 | finance.yahoo.comVanda Pharmaceuticals Announces Participation in the Jefferies Inaugural Biotech CNS/Neuro SummitSeptember 22, 2023 | stocknews.comBionano Genomics (BNGO) Challengers: 3 Biotech Innovators to Buy InsteadSeptember 5, 2023 | finance.yahoo.comWhy Shares of Vanda Pharmaceuticals Are Dropping on TuesdaySeptember 1, 2023 | finance.yahoo.com5 Biotech Stocks to Buy as New Drug Approvals Drive Industry ProspectsSeptember 1, 2023 | finance.yahoo.comAfter Plunging -7.98% in 4 Weeks, Here's Why the Trend Might Reverse for Vanda (VNDA)August 17, 2023 | fool.comVanda Pharmaceuticals (NASDAQ: VNDA)August 1, 2023 | finance.yahoo.comEarnings growth of 9.4% over 5 years hasn't been enough to translate into positive returns for Vanda Pharmaceuticals (NASDAQ:VNDA) shareholdersSee More Headlines Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2021Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:VNDA CUSIP92165910 CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees290Year Founded2002Profitability EPS (Most Recent Fiscal Year)$0.21 Trailing P/E Ratio19.24 Forward P/E RatioN/A P/E GrowthN/ANet Income$6.28 million Net Margins5.56% Pretax Margin8.31% Return on Equity2.19% Return on Assets1.84% Debt Debt-to-Equity RatioN/A Current Ratio6.32 Quick Ratio6.31 Sales & Book Value Annual Sales$211.85 million Price / Sales1.10 Cash Flow$0.11 per share Price / Cash Flow36.51 Book Value$9.32 per share Price / Book0.43Miscellaneous Outstanding Shares57,532,000Free Float53,102,000Market Cap$232.43 million OptionableOptionable Beta0.59 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Mihael H. Polymeropoulos M.D. (Age 63)Founder, President, CEO & Chairman of The Board Comp: $1.51MMr. Kevin Patrick Moran (Age 39)Senior VP, CFO & Treasurer Comp: $660.22kMr. Timothy Williams (Age 47)Senior VP, General Counsel & Secretary Comp: $724.38kMr. Joakim Wijkstrom (Age 57)Senior VP & Chief Marketing Officer Comp: $836.36kMr. Gunther Birznieks (Age 53)Senior Vice President of Business Development Comp: $690.83kMr. Scott L. HowellChief People OfficerMs. Elizabeth Van EveryHead of Corporate AffairsMore ExecutivesKey CompetitorsRigel PharmaceuticalsNASDAQ:RIGLLexicon PharmaceuticalsNASDAQ:LXRXAgenusNASDAQ:AGENCurisNASDAQ:CRISAnaptysBioNASDAQ:ANABView All CompetitorsInsiders & InstitutionsWellington Management Group LLPSold 24,591 shares on 12/1/2023Ownership: 0.319%American Century Companies Inc.Bought 135,022 shares on 11/30/2023Ownership: 0.377%Deutsche Bank AGBought 5,922 shares on 11/24/2023Ownership: 0.069%Walleye Capital LLCSold 43,284 shares on 11/21/2023Ownership: 0.448%Diversified Trust CoBought 22,065 shares on 11/17/2023Ownership: 0.120%View All Insider TransactionsView All Institutional Transactions VNDA Stock Analysis - Frequently Asked Questions How have VNDA shares performed in 2023? Vanda Pharmaceuticals' stock was trading at $7.39 on January 1st, 2023. Since then, VNDA stock has decreased by 45.3% and is now trading at $4.04. View the best growth stocks for 2023 here. Are investors shorting Vanda Pharmaceuticals? Vanda Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 2,040,000 shares, an increase of 21.4% from the October 31st total of 1,680,000 shares. Based on an average daily trading volume, of 1,300,000 shares, the days-to-cover ratio is presently 1.6 days. View Vanda Pharmaceuticals' Short Interest. When is Vanda Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 14th 2024. View our VNDA earnings forecast. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by $0.06. The biopharmaceutical company earned $70.10 million during the quarter, compared to analyst estimates of $73.50 million. Vanda Pharmaceuticals had a trailing twelve-month return on equity of 2.19% and a net margin of 5.56%. During the same period in the previous year, the firm posted $0.11 earnings per share. What ETFs hold Vanda Pharmaceuticals' stock? ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Horizon Kinetics Medical ETF (MEDX), iShares Neuroscience and Healthcare ETF (IBRN), iShares U.S. Pharmaceuticals ETF (IHE), What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO? 12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX). Who are Vanda Pharmaceuticals' major shareholders? Vanda Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (3.04%), Jacobs Levy Equity Management Inc. (1.68%), Federated Hermes Inc. (1.57%), Charles Schwab Investment Management Inc. (1.12%), Ameriprise Financial Inc. (1.10%) and Northern Trust Corp (0.98%). Insiders that own company stock include Aranthan Jones II, Gunther Birznieks, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell, Thomas Watkins and Timothy Williams. View institutional ownership trends. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:VNDA) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.